Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Phase I Trial of Combination Therapy with 90 y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin's Lymphoma, Final Report.

Hossein Borghaei, DO, MS, Russell J. Schilder, MD, Samuel Litwin, PhD, Michael Millenson, MD, Adam D Cohen, MD, Linda Thibodeau, RN, Mitchell R Smith, MD, PhD

Blood (2012) 120 (21): 2753.

https://doi.org/10.1182/blood.V120.21.2753.2753

Published: 2012

Journal Articles

Phase I Trial of Combination Therapy with 90 Y Ibritumomab Tiuxetan (Zevalin) and Gemicitabine in Patients with Non-Hodgkin’s Lymphoma.

Hossein Borghaei, DO, MS, Mitchell R. Smith, MD, Ph.D., Michael Millenson, MD, Linda Thibodeau, RN, Nicole Kamiensky, Russell J. Schilder, MD

Blood (2007) 110 (11): 4485.

https://doi.org/10.1182/blood.V110.11.4485.4485

Published: 2007

Journal Articles

Vinblastine, Mitoxantrone and Prednisone (MVP) Followed by Involved Field Radiotherapy (IF-XRT) for Early Clinical Stage Hodgkins’s Lymphoma: Long Term Follow-Up.

Danielle Shafer, DO, Hossein Borghaei, DO, Michael Millenson, MD, Nicos Nicolaou, MD, Tahseen I. Al-Saleem, MD, Nick C. Leasure, MD, Kris Padavic, RN, Mitchell R. Smith, MD, PhD, Russell J. Schilder, MD

Blood (2005) 106 (11): 2677.

https://doi.org/10.1182/blood.V106.11.2677.2677

Published: 2005

Journal Articles

Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) Induces Long-Term Responses in Patients with Relapsed or Refractory Follicular Lymphoma (FL).

Russell J. Schilder, MD, Thomas E. Witzig, MD, Ian Flinn, MD, Leo I. Gordon, MD, Christos Emmanouilides, MD, Hua Wang, MS, Katie Vo, Arturo Molina, MD.

Blood (2004) 104 (11): 2629.

https://doi.org/10.1182/blood.V104.11.2629.2629

Published: 2004

Journal Articles

Evaluation of Baseline Body-Weight Dosing of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL).

Gregory Wiseman, MD, Peter Conti, MD, Katie Vo, Russell J. Schilder, MD, Paul Foster, MD, Leo I. Gordon, MD, Christos Emmanouilides, MD, Dan Silverman, MD, Thomas E. Witzig, MD, Arturo Molina, MD

Blood (2004) 104 (11): 2634.

https://doi.org/10.1182/blood.V104.11.2634.2634

Published: 2004

NARROW

Phase I Trial of Combination Therapy with 90 y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin's Lymphoma, Final Report.

Phase I Trial of Combination Therapy with 90 Y Ibritumomab Tiuxetan (Zevalin) and Gemicitabine in Patients with Non-Hodgkin’s Lymphoma.

Vinblastine, Mitoxantrone and Prednisone (MVP) Followed by Involved Field Radiotherapy (IF-XRT) for Early Clinical Stage Hodgkins’s Lymphoma: Long Term Follow-Up.

Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) Induces Long-Term Responses in Patients with Relapsed or Refractory Follicular Lymphoma (FL).

Evaluation of Baseline Body-Weight Dosing of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL).

Email alerts

ASH Publications

American Society of Hematology

Phase I Trial of Combination Therapy with 90 y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin's Lymphoma, Final Report.

Phase I Trial of Combination Therapy with 90 Y Ibritumomab Tiuxetan (Zevalin) and Gemicitabine in Patients with Non-Hodgkin’s Lymphoma.

Vinblastine, Mitoxantrone and Prednisone (MVP) Followed by Involved Field Radiotherapy (IF-XRT) for Early Clinical Stage Hodgkins’s Lymphoma: Long Term Follow-Up.

Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) Induces Long-Term Responses in Patients with Relapsed or Refractory Follicular Lymphoma (FL).

Evaluation of Baseline Body-Weight Dosing of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only